Recent evidence links NLRP3 signaling to granulocytic recruitment in the TME and therapy antagonism, further supporting that inflammasome and tumor-promoting inflammation modulation may have strong antiglioma action [10]. The gene discussed is NLRP3; the disease is neoplasm.